Sutton LA, Rosenquist R. The advanced interaction between cell-intrinsic and cell-extrinsic elements driving the evolution of power lymphocytic leukemia. Semin Most cancers Biol. 2015;34:22–35.
Mansouri L, Papakonstantinou N, Ntoufa S, Stamatopoulos Ok, Rosenquist R. NF-κB activation in power lymphocytic leukemia: Some extent of convergence of exterior triggers and intrinsic lesions. Semin Most cancers Biol. 2016;39:40–8.
Delgado J, Nadeu F, Colomer D, Campo E. Persistent lymphocytic leukemia: from molecular pathogenesis to novel therapeutic methods. Haematologica. 2020;105:2205–17.
Mansouri L, Sutton LA, Ljungström V, Bondza S, Arngården L, Bhoi S, et al. Practical lack of IκBε results in NF-κB deregulation in aggressive power lymphocytic leukemia. J Exp Med. 2015;212:833–43.
Damm F, Mylonas E, Cosson A, Yoshida Ok, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL sufferers. Most cancers Discov. 2014;4:1088–101.
Robbe P, Ridout KE, Vavoulis DV, Dréau H, Kinnersley B, Denny N, et al. Entire-genome sequencing of power lymphocytic leukemia identifies subgroups with distinct organic and scientific options. Nat Genet. 2022;54:1675–89.
Della-Valle V, Roos-Weil D, Scourzic L, Mouly E, Help Z, Darwiche W, et al. Nfkbie-deficiency results in elevated susceptibility to develop B-cell lymphoproliferative issues in aged mice. Blood Most cancers J. 2020;10:38.
Mansouri, Thorvaldsdottir L, Sutton LA B, Karakatsoulis G, Meggendorfer M, Parker H, et al. Completely different prognostic affect of recurrent gene mutations in power lymphocytic leukemia relying on IGHV gene somatic hypermutation standing: a examine by ERIC in HARMONY. Leukemia. 2023;37:339–47.
Alves BN, Tsui R, Almaden J, Shokhirev MN, Davis-Turak J, Fujimoto J, et al. IκBε is a key regulator of B cell enlargement by offering detrimental suggestions on cRel and RelA in a stimulus-specific method. J Immunol. 2014;192:3121–32.
Barbaglio F, Belloni D, Scarfò L, Sbrana FV, Ponzoni M, Bongiovanni L, et al. Three-dimensional co-culture mannequin of power lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing brokers. Haematologica. 2021;106:2334–44.
Belloni D, Ferrarini M, Ferrero E, Guzzeloni V, Barbaglio F, Ghia P, et al. Protocol for technology of 3D bone marrow surrogate microenvironments in a rotary cell tradition system. STAR Protoc. 2022;3:101601.
Bertilaccio MTS, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, et al. A novel Rag2−/−γc−/−xenograft mannequin of human CLL. Blood. 2010;115:1605–9.
Ly G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription issue NF-κB by immediately concentrating on p65. J Biol Chem. 1998;273:33508–16.
Umezawa Ok, Breborowicz A, Gantsev S. Anticancer Exercise of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration. Oncol Res. 2020;28:541–50.
Bonfiglio S, Sutton LA, Ljungström V, Capasso A, Pandzic T, Weström S, et al. BTK and PLCG2 stay unmutated in one-third of sufferers with CLL relapsing on ibrutinib. Blood Adv. 2023;7:2794–806.
Primo D, Scarfò L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, et al. A novel ex vivo high-throughput assay reveals antiproliferative results of idelalisib and ibrutinib in power lymphocytic leukemia. Oncotarget. 2018;9:26019–31.
Morande PE, Sivina M, Uriepero A, Seija N, Berca C, Fresia P, et al. Ibrutinib remedy downregulates AID enzyme and proliferative fractions in power lymphocytic leukemia. Blood. 2019;133:2056–68.
Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human power lymphocytic leukemia modeled in mouse by focused TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955–60.
Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug improvement instrument for human power lymphocytic leukemia. Blood. 2006;108:1334–8.
Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta Ok, et al. Dichotomous Toll-like receptor responses in power lymphocytic leukemia sufferers underneath ibrutinib therapy. Leukemia. 2019;33:1030–51.
di Bergamo LT, Forestieri G, Loh JW, Singh A, Spina V, Zucchetto A, et al. Adaptation of power lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual illness and bypass signaling by way of the MAPK pathway. Clin Lymphoma Myeloma Leuk. 2021;21:S323–4.
Woyach JA, Smucker Ok, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Extended lymphocytosis throughout ibrutinib remedy is related to distinct molecular traits and doesn’t point out a suboptimal response to remedy. Blood. 2014;123:1810–7.
Liu T, Zhang L, Joo D, Solar SC. NF-κB signaling in irritation. Sign Transduct Goal Ther. 2017;2:17023.
Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in power lymphocytic leukemia. Blood. 2011;117:563–74.
Doménech E, Gómez-López G, Gzlez-Peña D, López M, Herreros B, Menezes J, et al. New mutations in power lymphocytic leukemia recognized by goal enrichment and deep sequencing. PloS One. 2012;7:e38158.
Rose-Zerilli MJJ, Gibson J, Wang J, Tapper W, Davis Z, Parker H, et al. Longitudinal copy quantity, complete exome and focused deep sequencing of “good danger” IGHV-mutated CLL sufferers with progressive illness. Leukemia. 2016;30:1301–10.
Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira AV, Pfeuffer L, et al. Unfavorable suggestions regulation of MAPK signaling is a crucial driver of power lymphocytic leukemia development. Cell Rep. 2023;42:113017.
